Tout, Mira <br/><br/>
Influence of FCGR3A-158V/F Genotype and Baseline CD20 Antigen Count on Target-Mediated Elimination of Rituximab in Patients with Chronic Lymphocytic Leukemia: A Study of FILO Group.  [electronic resource] 

 -  Clinical pharmacokinetics  06 2017 
 - 635-647 p.  digital 
<br/><br/> Publication Type: Clinical Trial, Phase II; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't 
<br/><br/><label>ISSN: </label>1179-1926 
<br/><br/><label>Standard No.: </label>10.1007/s40262-016-0470-8  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Antigens, CD20--metabolism<br/>Antineoplastic Agents--blood<br/>B-Lymphocytes--metabolism<br/>Body Surface Area<br/>Female<br/>Genotype<br/>Humans<br/>Leukemia, Lymphocytic, Chronic, B-Cell--drug therapy<br/>Lymphocyte Count<br/>Male<br/>Middle Aged<br/>Models, Biological<br/>Polymorphism, Genetic<br/>Receptors, IgG--genetics<br/>Rituximab--blood